President & Immunovant CEO · Roivant Sciences Ltd. · Roivant Sciences Ltd. — Stock Option (Right to Buy)
Side
M
Value
—
Shares
200.0K
Price
—
Executed
Jun 24, 2026
Disclosed
Jun 26, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Jun 24 executedJun 26, 2026 disclosed
ROIV · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Option exercise — administrative, little informational value
Relative size+1 / 25
No reported dollar value · 4.9% of prior position
Filing timing0 / 15
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+4 / 15
1 prior trade recorded in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
Pre-arranged plan-10
Executed under a Rule 10b5-1 trading plan
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Roivant Sciences Ltd. — Stock Option (Right to Buy)
Ticker
ROIV
Shares
200.0K
Price per share
$0
Execution date (reported)
Jun 24, 2026
Owned after transaction
4.24M shares
Rule 10b5-1 plan
Yes, as checked by the filer
Days from execution to publication
2
What this establishes
Venker Eric filed this Form 4 reporting a option exercise of ROIV on Jun 24, 2026. It became public on Jun 26, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
President & Immunovant CEO
Venker Ericcik:0001801917
Issuer
Roivant Sciences Ltd.cik:0001635088
Revision history · 0
No field has changed since this record was first ingested.
